- Home
- IMUX vs BEAT Comparison
IMUX vs BEAT Comparison
Compare IMUX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | BEAT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 84.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMUX | BEAT |
|---|---|---|
| Price | $0.55 | $2.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.00 | ★ $6.75 |
| AVG Volume (30 Days) | 1.5M | ★ 32.1M |
| Earning Date | 02-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.54 |
| 52 Week High | $1.39 | $4.00 |
Technical Indicators
Market Signals| Indicator | IMUX | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 59.11 |
| Support Level | $0.51 | $2.50 |
| Resistance Level | $0.60 | $3.18 |
| Average True Range (ATR) | 0.04 | 0.53 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 27.67 | 28.43 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.